Search results for " Respimat"

showing 3 items of 3 documents

Inhalation therapy devices for the treatment of obstructive lung diseases: the history of inhalers towards the ideal inhaler.

2020

Inhalation therapy allows conveying drugs directly into the airways. The devices used to administer inhaled drugs play a crucial role in the management of obstructive lung diseases such as asthma and chronic obstructive pulmonary disease (COPD). To ensure high bronchial deposition of the drug, a device should deliver a high proportion of fine particles, be easy to use, and provide constant and accurate doses of the active substance. Nowadays, four different types of inhalers are widely used: nebulizers, dry powder inhalers (DPIs), pressurized metered-dose inhalers (pMDIs), and soft mist inhalers (SMIs). Nebulizers can be used by patients unable to use other inhalers. However, they require l…

Drugmedicine.medical_specialtyRespiratory TherapyRespimatmedia_common.quotation_subjectSettore MED/10 - Malattie Dell'Apparato Respiratorio030204 cardiovascular system & hematologyMDI03 medical and health sciencesRoute of administrationPulmonary Disease Chronic Obstructive0302 clinical medicineAsthma COPD DPI MDI Nebulizer RespimatAdministration InhalationInternal MedicinemedicineCOPDHumans030212 general & internal medicineMetered Dose InhalersIntensive care medicineAsthmamedia_commonCOPDInhalationbusiness.industryInhalerNebulizers and VaporizersNebulizerEquipment Designmedicine.diseaseAsthma; COPD; DPI; MDI; Nebulizer; RespimatAsthmaRespimatDPINebulizerbusinessEuropean journal of internal medicine
researchProduct

A Non-Interventional Study of Tiotropium/Olodaterol versus Any Triple Combination Therapy for Chronic Obstructive Pulmonary Disease: The EVELUT® Stud…

2020

Roland Buhl,1 Michael Dreher,2 Stephanie Korn,1 Christian Taube,3 Christian Stock,4 Christoph M Zehendner,5 Anke Kondla,5 Claus F Vogelmeier6 1Pulmonary Department, Johannes Gutenberg University Mainz, Mainz, Germany; 2Clinic of Cardiology, Pneumology, Angiology and Internal Medicine Intensive Care, University Hospital RWTH Aachen, Aachen, Germany; 3Clinic for Pneumonology, University Medicine Essen – Ruhrlandklinik, Essen, Germany; 4Biostatistics + Data Sciences Corp, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany; 5HP Country Medical Affairs, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany; 6Department of Pneumology,…

medicine.medical_specialtytiotropium/olodaterolMedizinMuscarinic AntagonistsInternational Journal of Chronic Obstructive Pulmonary Disease03 medical and health scienceschemistry.chemical_compoundStudy ProtocolPulmonary Disease Chronic Obstructive0302 clinical medicineMaintenance therapySpiolto® Respimat®Internal medicineAdministration Inhalationmedicinemedia_common.cataloged_instanceCOPDHumansMulticenter Studies as Topic030212 general & internal medicineProspective StudiesEuropean unionTiotropium BromideAdrenergic beta-2 Receptor Agonistsmedia_commonCOPDbiologybusiness.industryInhalerOlodaterolGeneral MedicineLamamedicine.diseasebiology.organism_classificationLAMA/LABA/ICShumanitiesObstructive lung diseaseBenzoxazinesBronchodilator AgentsRegimen030228 respiratory systemchemistrytriple therapyDrug Therapy Combinationbusinesshormones hormone substitutes and hormone antagonistsInternational Journal of Chronic Obstructive Pulmonary Disease
researchProduct

The Effect of Tiotropium in Symptomatic Asthma Despite Low- to Medium-Dose Inhaled Corticosteroids: A Randomized Controlled Trial.

2014

BackgroundTiotropium, a once-daily long-acting anticholinergic bronchodilator, has demonstrated efficacy in patients with asthma who were symptomatic despite treatment with medium- to high-dose inhaled corticosteroids (ICS).ObjectiveThe objective of this study was to evaluate the efficacy and safety of once-daily tiotropium Respimat (5 μg or 2.5 μg), compared with placebo Respimat, as add-on therapy to low- to medium-dose ICS for adults with symptomatic asthma.MethodsA phase III, double-blind, placebo-controlled trial was conducted (NCT01316380). Adults with symptomatic asthma receiving low- to medium-dose ICS (200-400 μg budesonide or equivalent dose) and a pre-bronchodilator forced expira…

SpirometryBudesonideAdultMaleRespimatmedicine.drug_classSymptomaticAnticholinergicMildPlacebo03 medical and health sciences0302 clinical medicineBronchodilatorsAdrenal Cortex HormonesBronchodilatorControlAdministration InhalationImmunology and AllergyMedicineHumans030212 general & internal medicineTiotropium BromideBudesonideAnticholinergic; Asthma; Bronchodilators; Control; GINA; ICS; Mild; Respimat; Symptomatic; Tiotropium; Administration Inhalation; Adrenal Cortex Hormones; Adult; Asthma; Bronchodilator Agents; Budesonide; Disease Progression; Drug Combinations; Female; Humans; Male; Placebo Effect; Spirometry; Tiotropium Bromide; Treatment Outcome; Immunology and AllergyAsthmamedicine.diagnostic_testbusiness.industryTiotropiumTiotropium bromidemedicine.diseasePlacebo EffectGINAAsthmarespiratory tract diseasesRespimatBronchodilator AgentsDrug CombinationsTreatment OutcomeInhalation030228 respiratory systemTolerabilityICSSpirometryAnesthesiaAdministrationDisease ProgressionFemalebusinessmedicine.drugThe journal of allergy and clinical immunology. In practice
researchProduct